GRAL stock forecast, quote, news & analysis
GRAIL Inc is a healthcare company focused on developing technologies for early cancer detection... Show more
Why Grail (GRAL) Stock Is Up +26% in the Last 30 Days
Key Takeaways
- Grail (GRAL) shares rose roughly 26% over the 30 days through late August 2026, climbing from about $63.44 to $80.00.
- Second-quarter results beat consensus, with total revenue up 26% year over year and Galleri test volume up 35%.
- The U.S. FDA scheduled an advisory committee meeting for September 23, 2026, to review Grail's premarket approval application for Galleri.
- A completed $110 million strategic investment from Samsung and a Priority Health collaboration reinforced the commercial and regulatory narrative.
- Over the trailing three months, the stock advanced about 12%, recovering from a mid-2026 pullback tied to mixed clinical data.
Grail (GRAL) Company Overview and Market Position
Grail, Inc. is a Menlo Park, California-based healthcare company focused on early cancer detection. Its flagship product, Galleri, is a blood-based multi-cancer early detection (MCED) test designed to detect signals associated with more than 50 cancer types from a single blood draw, using a proprietary methylation-based platform. Grail became an independent public company following its 2024 separation from Illumina (ILMN).
Investors follow GRAL closely because of the large potential market for population-scale cancer screening, the company's extensive interventional clinical data, and its path toward U.S. regulatory approval and reimbursement. Grail's competitive positioning rests on studies such as PATHFINDER 2 and the NHS-Galleri trial, which the company argues distinguish Galleri from competing MCED tests supported primarily by case-control data.
Grail (GRAL) Stock Price Performance: Last 30 Days vs. Quarter
Over the last 30 days, GRAL climbed from a closing price of $63.44 on July 29, 2026, to $80.00 on August 28, 2026, a gain of approximately 26%. The advance was not linear; shares pulled back and recovered several times within the period, but the overall trend was decisively higher.
The broader three-month picture is more moderate but still positive. From a closing level near $71.68 in late May 2026, the stock has risen roughly 12% to the late-August close. That quarterly gain masks notable intra-quarter volatility: shares traded down toward the high-$50s in mid-June before rebounding through July and accelerating in August.
What Drove GRAL Stock Price in the Last 30 Days
The 30-day rally was powered by a combination of earnings, regulatory progress, and commercial momentum.
On August 5, 2026, Grail reported second-quarter results that came in ahead of consensus. Total revenue rose 26% year over year to $44.7 million, screening revenue grew 24% to $42.6 million, and Galleri test volume increased 35% to more than 61,000 tests. The company posted a net loss of $110.2 million, while adjusted gross profit rose 34% to $21.6 million. The results underscored accelerating demand even as the business remains loss-making.
The most significant catalyst arrived shortly after. On August 7, 2026, the U.S. Food and Drug Administration announced plans to hold an advisory committee meeting to review Galleri's premarket approval (PMA) application, with the meeting subsequently scheduled for September 23, 2026. The announcement lifted shares and refocused investor attention on the regulatory milestone that management has long described as the gateway to broader payer and employer adoption.
Additional tailwinds included the completion of a $110 million equity investment from Samsung and the start of a collaboration with Samsung C&T to commercialize Galleri in South Korea, with potential expansion into Japan and Singapore. Grail also announced a collaboration with Priority Health to expand employer-group access to Galleri, building on its digital-health and physician-channel growth.
What Drove GRAL Stock Performance Over the Last Quarter
The quarterly trend reflects a stock that absorbed difficult clinical news and then recovered as regulatory and commercial milestones materialized. Earlier in 2026, top-line data from the NHS-Galleri trial showed that the study did not meet its combined primary endpoint of reducing stage III and stage IV cancers, because an increase in stage III detections offset a decline in stage IV diagnoses. That result weighed on shares and contributed to the June pullback.
However, detailed data presented at the 2026 ASCO annual meeting highlighted secondary findings the company views as clinically meaningful, including higher overall cancer detection rates and a reduction in stage IV diagnoses. Those disclosures, along with FDA acceptance of the PMA filing, a completed sales-force expansion, growing digital-health volumes, and the Samsung investment, helped rebuild sentiment and set the stage for the August advance.
Trending AI Robots
For investors seeking a systematic approach to stocks such as GRAL, Tickeron's Trending AI Robots page offers a curated view of AI-powered trading bots. Tickeron hosts hundreds of AI trading bots that collectively trade thousands of tickers, but only the top-performing and most relevant bots appear in this section. The bots vary widely in strategy, timeframe, and performance metrics, giving traders options across different risk profiles and holding periods. Exploring the page can help investors see how algorithmic strategies are currently positioning across the market and identify tools that align with their own objectives.
GRAL Stock Forecast Drivers: What Investors Should Watch Next
Several factors will shape Grail's stock in the months ahead. The September 23, 2026, FDA advisory committee meeting is the clearest near-term catalyst, as the panel's assessment will inform a potential approval decision that management expects in the first part of 2027. Beyond approval, investors will watch for progress on Medicare and commercial reimbursement, which the company sees as essential to broader adoption.
Financial execution also matters. Grail reiterated 2026 revenue growth guidance in the 22% to 32% range, and upcoming quarterly results will test that outlook amid average-selling-price pressure. The resumption of an Illumina royalty obligation beginning in the fourth quarter of 2026 is expected to weigh on margins. Finally, competitive activity from other MCED tests, international commercialization with Samsung, and further publication of clinical data are all factors investors should monitor.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Momentum Indicator for GRAL turns positive, indicating new upward trend
GRAL saw its Momentum Indicator move above the 0 level on August 20, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 38 similar instances where the indicator turned positive. In of the 38 cases, the stock moved higher in the following days. The odds of a move higher are at .
Technical Analysis (Indicators)
Bullish Trend Analysis
The Moving Average Convergence Divergence (MACD) for GRAL just turned positive on August 19, 2026. Looking at past instances where GRAL's MACD turned positive, the stock continued to rise in of 17 cases over the following month. The odds of a continued upward trend are .
GRAL moved above its 50-day moving average on August 07, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where GRAL advanced for three days, in of 116 cases, the price rose further within the following month. The odds of a continued upward trend are .
The Aroon Indicator entered an Uptrend today. In of 104 cases where GRAL Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .
Bearish Trend Analysis
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In of 27 cases where GRAL's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where GRAL declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.411) is normal, around the industry mean (60.294). P/E Ratio (0.000) is within average values for comparable stocks, (157.231). GRAL's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (1.544). GRAL has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.007). P/S Ratio (19.531) is also within normal values, averaging (10.406).
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. GRAL’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. GRAL’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 91, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry MedicalSpecialties